	US 11,890,319 B2
	Antibody molecule-drug conjugates and uses thereof
Zachary Shriver, Winchester, MA (US); Obadiah Joseph Plante, Danvers, MA (US); Kai Li, Newton, MA (US); Karthik Viswanathan, Acton, MA (US); James C. Delaney, Cambridge, MA (US); Boopathy Ramakrishnan, Braintree, MA (US); and Andrew M. Wollacott, Milton, MA (US)
Assigned to VISTERRA, INC., Waltham, MA (US)
Appl. No. 16/478,696
Filed by VISTERRA, INC., Waltham, MA (US)
PCT Filed Jan. 18, 2018, PCT No. PCT/US2018/014224 § 371(c)(1), (2) Date Jul. 17, 2019, PCT Pub. No. WO2018/136626, PCT Pub. Date Jul. 26, 2018.
Claims priority of provisional application 62/492,641, filed on May 1, 2017.
Claims priority of provisional application 62/447,813, filed on Jan. 18, 2017.
Prior Publication US 2021/0283220 A1, Sep. 16, 2021
Int. Cl. A61K 38/00 (2006.01); A61K 38/17 (2006.01); A61K 47/68 (2017.01); A61P 31/04 (2006.01); C07K 16/12 (2006.01)

CPC A61K 38/1729 (2013.01) [A61K 47/6811 (2017.08); A61K 47/6815 (2017.08); A61K 47/6889 (2017.08); A61P 31/04 (2018.01); C07K 16/1203 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01)]

23 Claims

1. An antibody molecule-drug conjugate (ADC) comprising an anti-LPS antibody molecule and a covalently coupled antimicrobial peptide, wherein the antibody molecule comprises one or more motifs, wherein:

(I) the one or more motifs have the formula:

X₁(FGly′)X₂Z₂X₃Z₃

wherein FGly′ is a 2-formylglycine residue, a cysteine, or a serine;

Z₂is a proline or alanine residue;

X₁, X₂, and X₃are each independently any amino acid;

Z₃is a basic amino acid; and

(II) the antibody molecule comprises:

(i) a heavy chain comprising a heavy chain variable region (VH) comprising:

(a) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 108, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 146, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 107; or

(b) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 105, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 106, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 107; and/or

(ii) a light chain comprising a light chain variable region (VL) comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 138, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 142, and an LCDR3 comprising the amino acid sequence of any of SEQ ID NO: 112; and

(III) the antimicrobial peptide comprises the amino acid sequence of GGGKFFRKLKKSVKKRAKEFFKKPRVIGVSIPF (SEQ ID NO: 156).